Your shopping cart is empty
You are about to log out of

Would you like to place your order before you log out?










Act against Hib* disease

Stay vigilant and vaccinate

Haemophilus influenzae type b, a virulent and persistent respiratory pathogen,  continues to circulate and cause Hib disease in children1,2

• Therefore, continued vigilance and high Hib vaccination coverage rates are essential
   for effective disease prevention1

Depend on ActHIB vaccine for protection and reliability

ActHIB vaccine is indicated for the active immunization of infants and children 2 through 18 months of age for prevention of invasive Haemophilus influenzae type b disease.

Safety Information
The most common local and systemic adverse reactions to ActHIB vaccine include injection site erythema, swelling, and tenderness; fever irritability, drowsiness, and anorexia. Other adverse reactions may occur. ActHIB vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine. Vaccination with ActHIB vaccine may not protect all individuals.

Before administering ActHIB vaccine, please see full Prescribing Information

*Hib = Haemophilus influenzae type b.

References: 1. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what
are the next steps? J Pediatr. 2003;143(suppl):163-185. 2. Centers for Disease Control and
Prevention (CDC). Summary of notifiable diseases—United States, 2004. MMWR. 2006;53:23.









This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.